Povetacicept slashed protein leakage in IgA nephropathy in an interim phase 3 look

Povetacicept, an engineered protein that blocks two immune signals at once, cut protein leakage from the kidneys by about half at nine months in the interim analysis of the phase 3 RAINIER trial in IgA nephropathy [s1]. It is the newest entrant in a field that has seen a cluster of positive trials land within days of one another, and like most of those earlier read-outs, its evidence so far rests on a surrogate marker rather than on preserved kidney function [s1].

IgA nephropathy is an autoimmune kidney disease. The body produces a faulty, sugar-stripped form of the antibody immunoglobulin A; immune complexes built around it inflame the kidney's filtering units, spill protein into the urine, and slowly degrade the estimated glomerular filtration rate (eGFR) that measures kidney function. Povetacicept is a fusion protein that sops up both APRIL and BAFF, the two signals B cells rely on to churn out the culprit antibody — the same dual target as the drug atacicept, whose own phase 3 trial reported final results the same week [s1]. Blocking both signals, rather than APRIL alone, is the theory behind the class: starve the B cells of the growth factors they need and the supply of the faulty antibody should dry up at its source [s1].

What the trial did

RAINIER is a randomised, double-blind, placebo-controlled phase 3 trial [s1][s2]. Adults with biopsy-confirmed IgA nephropathy were assigned 2:1 to subcutaneous povetacicept 80 mg or placebo every four weeks [s1]. In all, 557 patients were randomised — 372 to the drug and 185 to placebo — but this prespecified interim analysis covered only the first 199 randomised patients (131 on povetacicept, 68 on placebo) followed to week 36 [s1]. That endpoint, the change in urinary protein, is the one that has supported accelerated approvals across this drug class; the trial's longer-term job is to show whether the protein benefit converts into slower loss of kidney function [s1].

What it found

The protein signal was large. The 24-hour urinary protein-to-creatinine ratio fell by 52.0% with povetacicept versus 4.3% with placebo, an adjusted difference of −49.8 percentage points (95% confidence interval −58.6 to −39.2; P<0.001) [s1]. The drug also drove down the disease's root cause: galactose-deficient IgA1, the faulty antibody itself, dropped by 77.4% on povetacicept while rising 9.1% on placebo, an adjusted difference of −79.3 percentage points (95% CI −82.2 to −75.9; P<0.001) [s1].

A third measure spoke to visible disease activity. Among patients who had blood in their urine at the start, that hematuria resolved in 85% of the povetacicept group versus 23% on placebo, an adjusted difference of 62 percentage points (95% CI 45 to 78; P<0.001) [s1]. Safety was in line with the rest of the class: adverse events occurred in 75% of the drug group and 78% of the placebo group, with serious adverse events in 3% and 4% respectively [s1].

How to read it

Taken on its own terms, this is a clean and sizeable interim result. The fall in galactose-deficient IgA1 is mechanistically satisfying — it shows the drug is hitting the antibody that starts the whole cascade, not just the downstream protein leak — and the hematuria data add a second, independent sign of reduced disease activity [s1].

The honest limitation is the same one that qualifies every drug here except the handful that have now reported eGFR data. Proteinuria is a surrogate: a reliable one, which is why regulators accept it for accelerated approval, but not the outcome patients care about. Whether halving protein leakage at nine months slows the march toward kidney failure is a question RAINIER's interim cannot answer, and the analysis covers fewer than 200 of the trial's 557 patients at an early timepoint [s1]. The confirmatory evidence this field has been waiting for arrived the same week for two other drugs — atacicept and sibeprenlimab — but for povetacicept it is still pending [s1].

What to watch

The result that matters is RAINIER's eGFR slope, which the full trial is designed to deliver once its larger population reaches longer follow-up [s1]. Until then, povetacicept looks like a potent proteinuria-lowering agent whose dual mechanism is well targeted, sitting in a line-up of similar drugs where the real contest — which agent best preserves kidney function, and whether any can be combined — is only beginning [s1]. The convenience of four-weekly subcutaneous dosing may count in its favour against rivals that require more frequent injections or intravenous infusions, but dosing schedules will matter far less than whichever drug ultimately shows the clearest effect on the eGFR slope [s1].

This article describes research and is not medical advice. Treatment of IgA nephropathy is a decision for treating clinicians.